Synonyms: 90Y-DOTA-hLL2 | 90Y-epratuzumab tetraxetan | 90Y-hLL2 | AMG-412 | IMMU-hLL2 | LymphoCide® (proposed proprietary name)
Compound class:
Antibody
Comment: Epratuzumab is a humanized monoclonal antibody. It is derived from the murine IG2a monoclonal antibody, LL2 (EPB-2). Epratuzumab has antineoplastic and antiinflammatory actions [1].
The antibody can be conjugated with tetraxetan (DOTA) which allows chelation of radionucleotides such as yttrium-90 [5]. |
Immunopharmacology Comments |
Epratuzumab was investigated for antiinflammatory actions in SLE, but was found not to be effective following Phase 3 trial evaluation [3,6]. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Systemic lupus erythematosus |
Disease Ontology:
DOID:9074 OMIM: 152700 Orphanet: ORPHA536 |
Epratuzumab is being investigated for antiinflammatory actions in SLE. |